Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
ANTIBODY AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2022/156799
Kind Code:
A1
Abstract:
The present invention relates to an antibody, which mainly binds to plasma prekallikrein, and the use of the antibody in the preparation of a drug for preventing or treating diseases associated with plasma kallikrein or plasma prekallikrein in subjects.

Inventors:
KE XIAO (CN)
LEI GANG (CN)
REN PENGFEI (CN)
FENG XIAO (CN)
LI JIANHONG (CN)
Application Number:
PCT/CN2022/073478
Publication Date:
July 28, 2022
Filing Date:
January 24, 2022
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
CHENGDU KANGHONG BIOTECHNOLOGY CO LTD (CN)
International Classes:
C07K16/36; A61K39/00; A61P7/10; A61P9/10; A61P29/00; C07K16/40; C12N5/10; C12N15/13; C12N15/63
Domestic Patent References:
WO2012094587A12012-07-12
Foreign References:
CN101495468A2009-07-29
CN111704672A2020-09-25
CN107405399A2017-11-28
Other References:
PAULA J. BUSSE, HENRIETTE FARKAS, ALEENA BANERJI, WILLIAM R. LUMRY, HILARY J. LONGHURST, DANIEL J. SEXTON, MARC A. RIEDL: "Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies", BIODRUGS, vol. 33, no. 1, 1 February 2019 (2019-02-01), NZ , pages 33 - 43, XP055707052, ISSN: 1173-8804, DOI: 10.1007/s40259-018-0325-y
Download PDF: